Rett syndrome is a devastating rare genetic childhood disorder primarily affecting girls. Merely 1 out of 10,000 girls are ...

Big Biotech Biogen is venturing into the city, paying $16 million in cash to partner up with an RNAi company to build next-gen central nervous system drugs. The research pact—inked with recently ...

The company has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome, and Acadia Pharmaceuticals Inc.

Stoke Therapeutics shares fell Tuesday after the company announced the resignation of its CEO. Dr. Edward Kaye is stepping down from the position Wednesday, with the company beginning a search ...

Stoke’s first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome and is expected to enter Phase 3 development in 2025.

Moreover, global biotech Biogen has built ties with Massachusetts-based RNA therapeutics company Stoke Therapeutics. The latter’s antisense oligonucleotide zorevunersen is presently in clinical trials ...

Latest Biotechnology and Biogen Inc., Insmed Incorporated Stock News As of June 30, 2025, Biogen Inc. had a $18.4 billion market capitalization, compared to the Biotechnology median of $128.4 million.

Biogen and Stoke Therapeutics have reached an agreement to develop and commercialize zorevunersen, a potential first-in-class disease-modifying therapy for Dravet syndrome, in all regions outside of ...

Biogen and Stoke Therapeutics have announced a partnership aimed at advancing a disease-modifying treatment for Dravet syndrome, with the deal worth $550m. Up to 38,000 people in the US, UK, EU and ...

CAMBRIDGE, Mass. - Biogen Inc. (NASDAQ: BIIB), a prominent biotechnology company with a $20.1 billion market cap currently trading near its 52-week low, and Stoke Therapeutics, Inc. (NASDAQ: STOK) ...

Biogen has entered a collaboration with Stoke Therapeutics to develop and commercialise zorevunersen to treat Dravet syndrome in all territories outside Canada, Mexico, and the US.